Page last updated: 2024-10-25

deferoxamine and Arrhythmias, Cardiac

deferoxamine has been researched along with Arrhythmias, Cardiac in 17 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.

Research Excerpts

ExcerptRelevanceReference
"We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years."7.67Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."5.56Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
"The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination."3.73Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006)
"In patients with thalassemia major (TM) who are non-compliant with long-term deferoxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional siderosis."3.72Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. ( Berant, M; Hershko, C; Miskin, H; Tamary, H; Yaniv, I, 2003)
"We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years."3.67Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."1.56Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
"Juvenile hemochromatosis is a rare genetic disorder that causes iron overload."1.31Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. ( Brunello, F; Camaschella, C; De Gobbi, M; Mazza, U; Paccotti, P; Pasquero, P, 2000)
"Severe arrhythmias were encountered in two of eight studies with 40 micrograms/ml iron and in two of seven studies with 80 micrograms/ml iron, but they were not found in any of the 29 control studies (p less than 0."1.28Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. ( Athias, P; Grynberg, A; Hershko, C; Link, G; Pinson, A, 1989)
"Severe congestive cardiac failure developed in a few weeks in a 44 year old man who had undergone porto-caval anastamosis for post-hepatitis cirrhosis one year previously and then treated for anaemia by repeated blood transfusion and chronic daily oral iron therapy."1.27[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent]. ( Azancot, I; Baudouy, P; Lombrail, P; Martin, E; Piekarski, A; Slama, R, 1983)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-199010 (58.82)18.7374
1990's1 (5.88)18.2507
2000's4 (23.53)29.6817
2010's1 (5.88)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Chuang, TY1
Li, JP1
Weng, TF1
Wu, KH1
Chao, YH1
Origa, R1
Danjou, F1
Cossa, S1
Matta, G1
Bina, P1
Dessì, C1
Defraia, E1
Foschini, ML1
Leoni, G1
Morittu, M1
Galanello, R1
Miskin, H1
Yaniv, I1
Berant, M1
Hershko, C2
Tamary, H1
Borgna-Pignatti, C1
Rugolotto, S1
De Stefano, P1
Zhao, H1
Cappellini, MD1
Del Vecchio, GC1
Romeo, MA1
Forni, GL1
Gamberini, MR1
Ghilardi, R1
Piga, A1
Cnaan, A1
Kolnagou, A1
Economides, C1
Eracleous, E1
Kontoghiorghes, GJ1
Baudouy, P1
Lombrail, P1
Azancot, I1
Piekarski, A1
Martin, E1
Slama, R1
Euler, DE1
De Gobbi, M1
Pasquero, P1
Brunello, F1
Paccotti, P1
Mazza, U1
Camaschella, C1
Strohmeyer, G1
Kaye, SB1
Owen, M1
Young, N1
Henry, W1
Nienhuis, AW1
Link, G1
Athias, P1
Grynberg, A1
Pinson, A1
Bernier, M1
Hearse, DJ1
Manning, AS1
Bolli, R1
Patel, BS1
Zhu, WX1
O'Neill, PG1
Hartley, CJ1
Charlat, ML1
Roberts, R1
Giardina, PJ1
Ehlers, KH1
Engle, MA1
Grady, RW1
Hilgartner, MW1
Festa, RS1
Wolfe, L1
Olivieri, N1
Sallan, D1
Colan, S1
Rose, V1
Propper, R1
Freedman, MH1
Nathan, DG1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901]150 participants (Actual)Observational2009-12-31Completed
A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia[NCT00005934]Phase 224 participants Interventional2000-06-30Completed
Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia[NCT00001958]Phase 2100 participants Interventional1999-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for deferoxamine and Arrhythmias, Cardiac

ArticleYear
[Iron storage disorders].
    Haematology and blood transfusion, 1978, Volume: 21

    Topics: Arrhythmias, Cardiac; Bloodletting; Deferoxamine; Diabetes Complications; Ferritins; Follicle Stimul

1978
Modern management of thalassemia.
    Pediatric annals, 1985, Volume: 14, Issue:9

    Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam

1985

Other Studies

15 other studies available for deferoxamine and Arrhythmias, Cardiac

ArticleYear
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Annals of hematology, 2020, Volume: 99, Issue:10

    Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati

2020
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer

2013
Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.
    European journal of haematology, 2003, Volume: 70, Issue:6

    Topics: Adolescent; Adult; Arrhythmias, Cardiac; Catheterization, Central Venous; Chelation Therapy; Deferox

2003
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Haematologica, 2004, Volume: 89, Issue:10

    Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe

2004
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Hemoglobin, 2006, Volume: 30, Issue:2

    Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod

2006
[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
    Archives des maladies du coeur et des vaisseaux, 1983, Volume: 76, Issue:10

    Topics: Adult; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Deferoxamine; Diastole; Echocardiography; Elec

1983
Role of oxygen-derived free radicals in canine reperfusion arrhythmias.
    The American journal of physiology, 1995, Volume: 268, Issue:1 Pt 2

    Topics: Animals; Antioxidants; Arrhythmias, Cardiac; Blood Pressure; Catalase; Coronary Circulation; Coronar

1995
Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin.
    Haematologica, 2000, Volume: 85, Issue:8

    Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adult; Arrhythmias, Cardiac; beta-Thalassemia; Chela

2000
Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.
    British medical journal, 1978, Feb-11, Volume: 1, Issue:6109

    Topics: Adolescent; Adult; Ambulatory Care; Arrhythmias, Cardiac; Child; Deferoxamine; Humans; Monitoring, P

1978
Treatment of primary hemochromatosis with deferoxamine.
    JAMA, 1979, Mar-16, Volume: 241, Issue:11

    Topics: Adult; Arrhythmias, Cardiac; Deferoxamine; Female; Heart Failure; Hemochromatosis; Humans; Male; Ped

1979
Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture.
    The Journal of laboratory and clinical medicine, 1989, Volume: 113, Issue:1

    Topics: Animals; Arrhythmias, Cardiac; Cells, Cultured; Deferoxamine; Heart; Iron; L-Lactate Dehydrogenase;

1989
Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart.
    Circulation research, 1986, Volume: 58, Issue:3

    Topics: Animals; Arrhythmias, Cardiac; Catalase; Coronary Circulation; Coronary Disease; Deferoxamine; Free

1986
The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction.
    The American journal of physiology, 1987, Volume: 253, Issue:6 Pt 2

    Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Coronary Disease; Coronary Vessels; Deferoxamin

1987
The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Annals of the New York Academy of Sciences, 1985, Volume: 445

    Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Deferoxamine; Echocardiography; El

1985
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    The New England journal of medicine, 1985, Jun-20, Volume: 312, Issue:25

    Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine

1985
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    The New England journal of medicine, 1985, Jun-20, Volume: 312, Issue:25

    Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine

1985
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    The New England journal of medicine, 1985, Jun-20, Volume: 312, Issue:25

    Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine

1985
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    The New England journal of medicine, 1985, Jun-20, Volume: 312, Issue:25

    Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine

1985